ArticleCancer immunology, immunotherapy : CII2026

Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer.

Ryo Yoshichika et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.